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Abstract: Endometriosis is characterized by the presence of endometrial tissue outside the uterus.
While endometriotic tissue is commonly localized in the pelvic cavity, it can also be found in distant
sites, including the brain. The origin and pathophysiology of tissue migration is poorly understood;
retrograde menstruation is thought to be the cause, although the presence of endometrium at
distant sites is not explained by this hypothesis. To determine whether dissemination occurs via
the bloodstream in women with endometriosis, we analyzed circulating blood for the presence
of endometrial cells. Circulating endometrial stromal cells were identified only in women with
endometriosis but not in controls, while endometrial epithelial cells were not identified in the
circulation of either group. Our results support the hypothesis that endometrial stromal cells may
migrate through circulation and promote the pathophysiology of endometriosis. The detection of
these cells in circulation creates avenues for the development of less invasive diagnostic tools for the
disease, and opens possibilities for further study of the origin of endometriosis.
Keywords: endometriosis; circulating endometrial cells; CD10; stromal cells; diagnostics;
liquid biopsy
1. Introduction
Endometriosis is a benign disease characterized by the growth of endometrial tissue outside of the
uterine cavity which affects approximately 15% of pre-menopausal women [1,2]. The main symptoms
of the disease are chronic pelvic pain, dysmenorrhea, dyspareunia and infertility/subfertility. All these
symptoms might affect patients psychologically, which often has repercussions on their social lives [3].
Endometriotic lesions are typically located in the pelvic region; however, distant lesions have been
reported in lung, liver, and even in the eyes [4]. Several explanations for the origin of endometriosis
have been proposed, but no clear consensus has been reached. The most accepted explanation is
Sampson’s hypothesis, which describes retrograde menstruation [5,6]. However, this theory has
some limitations; for example, the 95% of women have retrograde menstruation, while only the 15%
manifest the disease [7]. Therefore, other explanations, such as coelomic metaplasia or embryonic rests,
have also been proposed [5,7]. Nonetheless, none of these hypotheses account for cases of distant
lesions identified outside the pelvis. Alternatively, bone marrow or endometrial stem cells could
play a role in the origin of endometriosis, as shown in some studies where bone marrow stem cells
engrafted endometriotic lesions [8–11]. Moreover, rodent models of endometriosis demonstrated that
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endometriotic cells migrated from lesions to eutopic endometrium [12], suggesting that they migrated
through extravasation. Interestingly, this process seems to be regulated by an epithelial-mesenchymal
transition (EMT), since the migrating cells express aberrant epithelial markers in the stroma [12]. EMT
is an important process in metastasis, as cells are able to change their phenotype from epithelial
to a mesenchymal type, which allows the extravasation of the cells, enabling them to migrate to
other tissues. Additionally, hematogenous dissemination of mesenchymal stem cells occurs in rodent
models of endometriosis, suggesting the presence of circulating endometriotic cells [13]. The aberrant
expression of epithelial markers in the stromal compartment of the eutopic endometrium has also
been demonstrated in humans [14] by our group. Epithelial cells, expressing cytokertin (CK) and
E-Cadherin, were found in the stromal layer of eutopic endometrium co-expressing the putative
stem cell marker LGR5 [14,15]. In our study, EMT could play a role in the migration of endometrial
LGR5+CK+ cells, since they also overexpressed MMP12, a matrix metalloproteinase involved in the
degradation of the extracellular matrix and involved in the EMT process [16]. Taken together, these
findings suggest that endometrial cells might be able to migrate from eutopic endometrium to ectopic
sites through circulation thanks to an EMT process.
Endometriosis is generally diagnosed by laparoscopy, an invasive procedure, with subsequent
histopathologic assessment of tissue samples. Therefore, new and less invasive approaches would
aid the diagnostic process. Although attempts have been made to identify biomarkers in the eutopic
endometrium, in serum or plasma, in peritoneal fluid, and in urine [17], no biomarkers to date
demonstrate adequate specificity or sensitivity.
Liquid biopsy is a novel technique that consists of detecting and isolating circulating tumor cells
as source for genomic information for cancer patients enabling a potential non-invasive diagnosis.
Indeed, the identification of circulating cells in blood has been used for the diagnosis of cancers such
as colon, prostate, renal, pancreatic, and lung cancer [18–22]. Circulating tumor cells (CTCs) are shed
into the bloodstream from primary or metastatic tumors, and have the potential to initiate metastasis in
distant tissues or organs [23,24]. Cancer cells are shed from the primary tumor into the circulation prior
to the presentation of clinical symptoms and may metastasize at distant sites [25], sparking interest
in the development of new tools using liquid biopsy for CTCs isolation. Numerous methods have
been developed to detect CTCs, primarily based on the detection of epithelial cell adhesion molecule
(EpCAM). The Food and Drug Administration (FDA) has approved the CellSearch® platform for the
detection of CTCs, and it is being used successfully to detect them in breast cancer [26–29]. However,
not all cancers or diseases shed circulating cells with epithelial origin into the bloodstream. Moreover,
EMT seems to be common among circulating cells, and they may lose their epithelial markers, making
their detection in blood much more difficult [30,31]. Therefore, alternative methods to identify not
only epithelial, but also stromal cells, need to be assessed.
The aim of our study was to evaluate the presence and nature of circulating cells in women with
endometriosis through liquid biopsy using a user friendly circulating rare cells (CRCs) isolation device
based on size exclusion to capture not only epithelial, but also stromal circulating cells in blood. For
this reason, in order to evaluate the phenotype of circulating cells, we labeled the obtained cells with
the epithelial and stromal markers cytokeratin (CK) and CD10, respectively.
2. Results
Isolation and Detection of Circulating Endometrial Cells (CECs): Immunofluorescence
We found a mean of 14.75 circulating endometrial cells (CECs; range 0–57) in the group with
endometriosis (n = 8) and no CECs in the four healthy donors. The counts of total cells present in the
total area of the filter are listed in Table 1.
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Table 1. Patient characteristics and number of circulating endometrial cells in each patient.
Patient Code Age Menstrual Cycle Phase Type of Endometriosis Stimulation
CECs
CK CD10
1 26 Proliferative Control rFSH (antagonist) 0 0
2 31 Proliferative Control rFSH (antagonist) 0 0
3 21 Proliferative Control rFSH (antagonist) 0 0
4 22 Proliferative Control rFSH (antagonist) 0 0
5 37 Proliferative Endometrioma rFSH (antagonist) 0 11
6 36 Proliferative DIE rFSH (antagonist) 0 5
7 42 Secretory Endometrioma HRT 0 17
8 32 Proliferative DIE GnRH downregulation + HRT 0 0
9 30 Menstrual DIE HRT 0 3
9 30 Proliferative DIE HRT 0 57
9 30 Secretory DIE HRT 0 22
9 30 Proliferative DIE GnRH downregulation + HRT 0 3
The table shows the number of patients included in the study, their age, the phase of the menstrual cycle the date of
sample collection, the type of endometriosis (or control patients) and, the treatment that was used in the moment
of the blood collection. In addition, the number of CECs found after immunofluorescence is also shown for both
tested markers (CK and CD10). CECs: circulating endometrial cells; CK: cytokeratin; CD10: Common Acute
Lymphoblastic Leukemia antigen; DIE: deep infiltrating endometriosis; GnRH: gonadotropin releasing hormone;
rFSH: recombinant follicular stimulating hormone; HRT: hormone replacement therapy.
Surprisingly, we observed CECs expressing the endometrial stromal marker CD10, also called
CALLA (common acute lymphoblastic leukemia antigen), but did not find any cytokeratin (CK)
positive cells in the endometriosis group nor in the control group. In addition, no cells expressing
CD10 displayed co-localization with the CK marker. An example of the presence of CD10+ cells in
circulation in each of the four patients with endometriosis where the marker was found is shown in
Figure 1.
Interestingly, the only instance where no CEC were found (patient 8) was a patient with deep
infiltrating endometriosis (DIE) who had been under GnRH agonist suppression treatment for two
months before sample collection. Moreover, another patient who had DIE (patient 9) underwent
surgery four months before the sample collection, and only three CECs expressing CD10 were found in
circulation when she was under hormone replacement therapy (HRT) with GnRH downregulation.
Blood from patient 9 was taken at three additional time points (during the proliferative, secretory, and
menstrual phases); surprisingly, CD10+ cells were found in all cases. However, when she was under
GnRH treatment, only three CD10+ cells were found in circulation, whereas when the agonist was
removed, 57 CD10+ cells were found during the proliferative phase of the menstrual cycle and 22
CD10+ cells during the secretory phase.
No differences in the number of CECs across the phases of the menstrual cycle were observed,
nor were there any differences among different ages of women. Indeed, in patient 9, no differences
between cycle phases were observed.
Int. J. Mol. Sci. 2019, 20, 3740 4 of 12
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 4 of 13 
 
 
Figure 1. Immunofluorescence of CD10 in endometriosis patients. This figure shows an example of 
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(DAPI, blue), CD10 positive cells (Alexa555, Red) and merge pictures are shown for each patient. The 
field was taken at ×40 magnification. A manual amplification of a CD10 positive cell in each case is 
shown in the figure. 
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are normally present in a liquid biopsy. CD10+ cells (stromal cells) were present in the peripheral 
Figure 1. Immunofluorescence of CD10 in endometriosis patients. This figure shows an example of the
CD10 positive cells found in circulating blood of endometriosis patients. The patient ID is showed in
the second column and the number of CD10 positive cells in the third column. Nuclear staining (DAPI,
blue), CD10 positive cells (Alexa555, Red) and merge pictures are shown for each patient. The field
was taken at ×40 magnification. A manual amplification of a CD10 positive cell in each case is shown
in the figure.
3. Discussion
Here, we demonstrate for the first time that the ScreenCell® device may be used to isolate CECs
from peripheral blood in women with endometriosis, even with the very small amount of CECs that
are normally present in a liquid biopsy. CD10+ cells (stromal cells) were present in the peripheral
blood of women with endometriosis, but not epithelial cells. ScreenCell® Cyto Technology isolates
circulating cells based on size exclusion. An advantage of this device is its rapid processing time; the
assay can be completed in about 15 min. A series of 23 patients with cutaneous melanoma, a cell type
that does not express EpCAM, revealed the utility of the ScreenCell® Cyto device for enumeration of
CTCs, cytological analysis, and analysis of genetic mutations [32].
We used CD10 to identify stromal endometrial circulating cells, since it is a marker expressed by
endometrial stromal cells in normal endometrium as well as in the stromal compartment of endometrial
neoplasms [33], and in ectopic endometriotic lesions [34]. The presence of CD10 has also been observed
in some B and T lymphocytes in patients with leukemia [35,36]. However, none of the tested patients
had leukemia. In addition, CD10+ endometrial cells are usually larger than hematopoietic cells and
most of the cells pass through the filter while circulating CECs are retained. Indeed, the filter pores
measure 7.5–8 µm in diameter and are able to retain 85–100% of “tumor” or endometrial cells and only
0.1% of common blood cells [32].
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We found stromal cells (CD10+ cells) but no epithelial cells in the circulating blood of endometriosis
patients. One explanation for the absence of epithelial circulating cells may be that cells smaller than 8
µm could be missed using this filtration technique. Alternatively, epithelial cells undergo EMT when
they spread to the blood circulation and do not express CK. Invasive cancer cells migrate through
the stroma and vessels as single cells or in clusters and, while single cells usually undergo EMT,
clusters harbor mesenchymal cells [37], suggesting that EMT plays an important role in the initiation of
metastasis [36]. Even though endometriosis is a benign disease, it is believed that mesenchymal stem
cells could be responsible for the endometriotic lesions observed in organs far from the endometrial
cavity [13]. Our findings support this hypothesis, as we found mesenchymal circulating cells only
in patients with endometriosis but not in healthy patients. Since it was not possible to determine
the origin of the stromal cells found in blood circulation, it is not clear if these stromal cells migrate
through extravasation from the eutopic endometrium or, on the other hand, from the endometriotic
lesion, enhancing the spread of the disease to distant sites. Alternatively, it is known that tissues
derived from coelomatic epithelial and mesenchymal cells can differentiate into epithelial and stromal
cells [7] and the environment in peritoneal cavity of women with endometriosis is altered as well [38].
Therefore, an unproven but plausible explanation could be that immune cells, pro-inflammatory
cytokines/chemokines, adhesion molecules, among other factors, could activate the differentiation of
quiescent endometrial progenitor stem cells into endometrial cells and lead to the development of
endometriotic lesions during pubertal development [7].
Several efforts have been made for the detection of CTCs in gynecological cancers by using
different approaches. However, to our knowledge, only two groups have investigated circulating cells
in peripheral blood in women with endometriosis [39,40]. A summary of the approaches performed in
different gynecological diseases is shown in Table 2.
Table 2. The table shows the studies performed in gynecological diseases (endometrial, breast and
ovarian cancer and, endometriosis) [27–29,39–53]. And it describes which methodology was used
for the detection of circulating cells. The table also contains references of reviews specialized on
this topic. EpCAM: epithelial cell adhesion molecule; RTqPCR: real time quantitative PCR; ICC:
immunocytochemistry; IF: immunofluorescence.
Gynecological Pathology Benign/Malignant CTCs/CECs Detection Technology References
Endometrial cancer Malignant
EpCAM based; CellSearch® and IF [41]
EpCAM based; CellSearch® and IF [46]
Density-based, Enrichment (Oncoquick) and RTqPCR [44]
RTqPCR and flow cytometry [43]
Size-Based Enrichment (Metacell®) and
Immunodetection
[53]
RTqPCR [45]
Review [49]
Breast cancer Malignant
EpCAM based; CellSearch® [27]
EpCAM based; CellSearch® [29]
EpCAM based; CellSearch® [28]
Ovarian cancer Malignant
EpCAM based; magnetic beads [50]
ICC [51]
Immuomagnetic bead screening and RTqPCR [47]
Review [52]
Immunomagnetic microspheres [42]
Microfluidic system [48]
Endometriosis Benign
In culture enrichment; MetaCell® [39]
IF staining via microfluidic chips [40]
ScreenCell® This study
In the case of endometriosis, one group used MetaCell® Technology, in which cells are enriched by
filtration. CECs were cultured and underwent immunohistochemistry (IHC) with CK, vimentin, and
CD10 markers to confirm endometrial origin [39]. CECs were identified in 4/17 cases of endometriosis.
In this study, we used ScreenCell® device, which is also based in size exclusion method, therefore, the
loosing or lack of epithelial markers on the cell surface is solved and all types of circulating cells in
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blood can be captured. One advantage of the ScreenCell® device when compared to MetaCell® is that
it is able to fix and label the cells directly into the filter without the need to culture them, ensuring
that the surface markers do not change during the processing of the sample. The second group used
microfluidic chips and found that 89.5% of endometriotic patients had circulating CECs, while only
15% of the healthy controls had circulating CECs [40]. They identified CECs by positive expression of
the vimentin/CK and estrogen/progesterone receptor. We obtained CECs in all endometriotic patients
except one (4 out of 5 samples). Interestingly, the only patient in which CECs were not detected had
been under agonist (GnRH) suppression for two months after laparoscopic intervention. The first time
that blood samples were obtained from this patient was during the proliferative phase underHRT
treatment after GnRH downregulation. At this time, only three CD10+ cells were found in circulation.
The second collection time was during the menstrual phase, right before starting an HRT cycle and
without agonist treatment. After that, two more samples were taken at the proliferative and secretory
phase during HRT treatment. Surprisingly, in the last cycle without GnRH downregulation, the
number of positive stromal cells in circulation increased considerably; 57 and 22 CD10+ cells were
found, respectively. These findings suggest that CECs might be an indicator of disease activity, since
some studies have demonstrated that CTCs are correlated with disease progression [54]. We included
patients with controlled ovarian stimulation (COS) and HRT and, according to our data, the type of
endometrial preparation does not seem to affect to the number of CECs found.
A strength of this study is that we analyzed fixed cells directly on the membrane of the filter,
indicating that the cells did not have a chance to change their morphology or their gene expression. In
addition, another advantage when using ScreenCell® device is that it is a very friendly user device,
which is easy to manipulate and the whole filtration process is very fast, obtaining the CECs in less than
15 min. On the other hand, this study presents several limitations. First, the sample size is small, and
samples were obtained in different phases of the menstrual cycle. However, Chen et al. did not find
any significant difference among menstrual phases when they tested 57 patients [40], also suggesting
that phases of the cycle do not affect to the number of CECs. Another limitation is that none of the
control patients underwent laparoscopy. Instead, we included proven fertile 18–35 year-old donors
with no signs or symptoms of endometriosis.
In conclusion, we have identified stromal endometrial cells in circulating blood from women with
endometriosis, providing evidence to assist the development of new and less invasive tool for the early
diagnosis of endometriosis. In addition, our results suggest that stromal cells could be involved in the
pathophysiology of endometriosis by migrating through circulation to distant sites. However, further
studies are required to assess the feasibility of utilizing CECs in the diagnosis of endometriosis and to
investigate the nature of endometrial cell migration.
4. Material and Methods
4.1. Subjects
Samples were collected between June 2017 and January 2018 at IVI Barcelona S.L. and Hospital
Vall Hebron (Barcelona, Spain) and all participants signed an informed consent. Nine participants were
included in the study: four healthy women who were egg donors and five patients with endometriosis
diagnosed by laparoscopy. None of the participants had previous records of oncological pathologies.
From the five endometriosis patients, two were stimulated with recombinant follicular stimulating
hormone (rFSH), in an antagonist cycle (patients 5 and 6). Three were under HRT cycle (patients 7, 8
and 9) and two of them with previous GnRH downregulation (patients 8 and 9). Briefly, HRT consisted
of estradiol at oral dosages of 6–8 mg/day for 10–12 days and then adding 800 mg/day of natural
micronized progesterone vaginally. Patient 9 donated blood at four different time points after surgery:
while she was under HRT treatment (at the proliferative phase), while under GnRH downregulation,
and only with HRT treatment (during the proliferative, secretory and menstrual phases of the cycle).
Figure 2 shows the protocols of the different treatments in patients with endometriosis.
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Figure 2. Hormonal treatments. (A) Antagonist protocol: After menses, rFSH is administrated for
aro nd 10–12 days. Wh n th follicles reach around 12mm, the antago ist (GnR An) is administrated.
At the end of the stimulation cycle, hCG is injected before the oocyte re ri v l. (B) HRT protocol: After
menses, v l rate estradiol at oral dosages (6–8 mg/day) for 10–12 days is administrated. Then, 800
mg/day of natu al micronized p ogesterone vaginally are added to the estradiol treatment for 15 more
days. (C) GnRH downregulation protocol + HRT: in luteal phase, one injection of triptorelin 3.75 (GnRHa)
is administrated and subsequently for two more months. rFSH: recombinant follicle stimulating
hormone; GnRHa: gonadotropin releasing hormone agonist; GnRHAn: gonadotropin releasing
hormone antagonist; HRT: hormonal replacement treatment; hCG: human chorionic gonadotropin.
All participants were pre-menopausal and aged between 18 and 44. The mean age of study
participants was 30.77 years (range 21–42). The mean age in the control group was 25 years (range
21–31) and 35.4 years (range 30–42 years old) in the endometriosis group. Patient characteristics are
listed in Table 1.
Among the five endometriotic patients, three were diagnosed with DIE (patients 5, 8, and 9)
and the other two presented ovarian endometriomas (patients 6 and 7). Patient 6 manifested a 3 cm
endometrioma in the right ovary and a 2 cm endometrioma in the left ovary, whereas patient 7 had
a 2 cm endometrioma in the right ovary. Among the patients with DIE, patient 5 presented bowel
and vesical lesions and a 2 cm adenomyoma as well. Patient 8 showed pelvic, utero-sacral and bowel
lesions and multiple infracentimetric endometriotic lesions in both ovaries (stage IV), whereas patient
9 presented multiple bowel and pelvic adhesions together with a 2 cm endometrioma in the right
ovary (stage IV). Regarding reproductive outcomes, two patients had previously conceived healthy
children (patients 6 and 8) after assisted reproductive technology (ART) treatments, while the other
three had never been pregnant.
Two samples from two different patients were obtained during the mid-late follicular phase of
COS with antagonist (patients 5 and 6) and the rest of the samples from the endometriotic group
were obtained in women undergoing HRT for a frozen embryo transfer. Three of the samples from
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two different patients were obtained during the proliferative phase. Two samples from two different
patients (patients 7 and 9) were obtained in the secretory phase and one in the menstrual phase of the
cycle (patient 9). Among the patients undergoing HRT, two of the samples (from patients 8 and 9)
were obtained after GnRH agonist down-regulation (one after three months of GnRH down regulation
and the other after only one month of GnRH downregulation).
4.2. Sample Collection
Twelve blood samples of 10 mL were obtained in K2-EDTA tubes (Becton Dickinson, Franklin
Lakes, NJ, USA). Proven healthy donor samples were collected during COS. To avoid possible cutaneous
contamination from epithelial cells taken by the needle during sampling, the first milliliter of blood
obtained was always discarded. After blood collection, tubes were immediately inverted ten times and
kept at 4 ◦C until they were processed. The ethics committee of IVI Barcelona S.L. (1611-BCN-080-XS; 6
June 2016) and Vall Hebron (PR(AMI)410/2016; 7 July 2017) approved the use of the blood samples.
4.3. Sample Processing
To obtain circulating endometrial cells (CECs), we utilized ScreenCell® Cyto Technology
(ScreenCell®Cyto CY 4FC; ScreenCell SA, Paris, France). We followed the manufacturer’s instructions,
briefly outlined below and in Figure 3.Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 9 of 13 
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Figure 3. ScreenCell®Cyto Technology process. First, blood is collected and mixed with dilution buffer
(Incubation). After, there is a filtration process, washing and fixation with PFA 4%. Then, IF can
be performed on the filter. After mounting, the IF is visualized by a fluorescence microscope. PBS:
phosphate buffered saline; PFA: paraformaldehyde; IF: immunofluorescence.
First, the ScreenCell® FC dilution buffer was prepared. After that, 3 mL of blood were transferred
into one 15 mL sterile conical tube. Then, 4 mL of dilution buffer was added and inverted five times
and incubated for 8 min at room temperature (RT). uring this process, red blood cells became lysate.
After incubation, the blood was filtered. The filter co tai s ores of iffere t sizes (6.5 ± 0.33 µm) that
are randomly distributed around the entire filter su face. Then, 1.6 mL of 1× phosphate buffered saline
(PBS) was added to wash he filter of deb is. The filter was then placed on a piece of Whatman® paper
to be dried. After, it was placed it in p24 well and fix d with 4% paraformaldehyde for 10 min. It was
then washed thre time for 5 min with 1× PBS. Finally, immunofluorescence was performed.
4.4. Detection of CECs: Immunofluorescence
To determine whether CECs were of epithelial or stromal origin, cells were stained with the
epithelial marker CK and t e stromal endometrial marker CD10. Previously, the antibody concentration
needed for the detection of both markers was opti ized by using primary endometrial epithelial and
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stromal cells previously cultured. In the optimization process, three different concentrations of the
primary antibodies (1:50, 1:150, and 1:250) were tested and two types of negative controls were used:
unstained cells and cells stained only with the secondary antibody but not with the primary. After that,
the optimal concentration for the primary antibodies was set as 1:100 for CK and 1:250 for CD10.
The ScreenCell® filters containing the cells were blocked with PBS 0.1% of Tween detergent
(Sigma Aldrich, Sant Louis, MO, USA) and 5% of normal goat serum (NGS)(Thermo Fisher Scientific,
Waltham, MA, USA) and 5% of bovine serum albumin (BSA) (Sigma Aldrich, Sant Louis, MO, USA)
for 30 min at RT. Cells were then incubated for one hour at RT with the primary antibodies against CK
and CD10, monoclonal mouse anti-pan-cytokeratin antibody (Santa Cruz Biotechnology, Inc., Santa
Cruz, TX, USA) and rabbit anti-CD10 polyclonal antibody (BioNova bioNova científica, s.l., Madrid,
Spain), at a dilution of 1:100 and 1:250, respectively. The antibodies were diluted in PBS 0.1% Tween
and 3% of NGS and 3% of BSA to reduce background. After incubation with the primary antibodies,
cells were washed three times with 1x PBS for 5 min and incubated with the secondary antibodies
for 30 min at RT in the dark. Goat Alexa488 anti-mouse (Life Technologies, Carlsbad, CA, USA) and
goat Alexa555 anti-rabbit (Life Technologies, Carlsbad, CA, USA) were used to detect CK and CD10,
respectively, both in a dilution 1:500. After incubation, filters were washed three times with 1× PBS
for 5 min and were mounted on glass slides covered with a 7 mm circular coverslip. ProLong Gold
antifade reagent with 6-diamino-2-phenylindole (DAPI, Life Technologies, Carlsbad, CA, USA) was
used to detect nuclear DNA. Visualization of the stained cells was performed with an OlympusBX61
microscope (Olympus corporation, Tokio, Japan). All positive cells were counted in the whole area of
the filter (7 mm).
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